Chadwick Jeremy G 4

What Happened

• Jeremy G. Chadwick, Chief Operating Officer of Kymera Therapeutics (KYMR), disposed of a total of 17,184 shares in multiple open-market sales on May 26–27, 2026, generating approximately $1,373,290 in gross proceeds.
• Individual transactions reported: 3,730 @ $78.36 ($292,271); 324 @ $79.17 ($25,651); 3,800 @ $79.39 ($301,691); 4,500 @ $80.02 ($360,111); 551 @ $80.71 ($44,470); 3,679 @ $81.50 ($299,850); 600 @ $82.08 ($49,246). Overall sale prices reported as weighted averages across multiple trades, with per-trade ranges provided in the filing.

Key Details

• Transaction dates: May 26–27, 2026 (filed with the SEC on May 27, 2026).
• Total shares sold: 17,184; total gross proceeds: ≈ $1,373,290.
• Price range across transactions: approximately $77.99 to $82.15 per share (weighted-average ranges disclosed in footnotes).
• Notable footnotes: some sales were automatic to cover tax withholding obligations; some sales were executed pursuant to a Rule 10b5-1 trading plan (dated Dec 10, 2025); several entries report weighted-average prices across multiple trades and disclose price ranges.
• Shares owned after the transactions: not specified in the information provided.
• Timeliness: Filing date (May 27, 2026) follows the trades on May 26–27 and appears to be timely (no late-filing flag noted).

Context

• The filing codes indicate these were sales (S). Footnotes show a mix of mandatory tax-withholding dispositions and trades under a pre-established 10b5-1 plan — both are common, routine ways executives reduce share balances and manage tax obligations.
• For retail investors: purchases or new awards can be more indicative of insider confidence than routine sell-to-cover or plan-driven sales. This report documents disposals, not an acquisition or exercise followed by a hold.